American Urological Association

American Urological Association Names New Treasurer-Elect

Retrieved on: 
Donnerstag, November 2, 2023
National Association, MIT, AUA, Urology, American Urological Association, MD, Organization, Nativ College Leadership Program, Leadership Institute, Executive Committee, Business, Continence, National Association for Continence, Accounting, Massachusetts Institute of Technology, Treasurer, Management

BALTIMORE, Nov. 2, 2023 /PRNewswire/ -- The American Urological Association (AUA) is pleased to announce Jennifer Miles-Thomas, MD, has been named Treasurer-elect, a position she will assume in May 2024 with ratification at the AUA Annual Business Meeting, and hold until May 2025 when she will become Treasurer of the Association for a four-year term.

Key Points: 
  • BALTIMORE, Nov. 2, 2023 /PRNewswire/ -- The American Urological Association (AUA) is pleased to announce Jennifer Miles-Thomas, MD, has been named Treasurer-elect, a position she will assume in May 2024 with ratification at the AUA Annual Business Meeting, and hold until May 2025 when she will become Treasurer of the Association for a four-year term.
  • As the Treasurer-elect, Dr. Miles-Thomas will have the vital role of ensuring the financial security of both the AUA and Urology Care Foundation.
  • This includes overseeing financial reporting and compliance with both Boards of Directors and various stakeholders, including AUA members.
  • She is currently the President and CEO of Urology of Virginia, is a board member of the Schellhammer Urological Research Foundation, American Association of Clinical Urologists, as well as the National Association for Continence, and holds various leadership positions with other organizations.

Avenda Health's Revolutionary AI Mapping Tool for Prostate Cancer Achieves Landmark Category III CPT Code Designation

Retrieved on: 
Mittwoch, November 1, 2023
FDA, Urology, American Medical Association, Physician, Pathology, Health, Avenda Systems, Prostate cancer, Research, AMA, Probability, American Urological Association, Category, Unfold, CPT, Cancer, Patient, Map, Medical imaging, Medical device

CULVER CITY, Calif., Nov. 1, 2023 /PRNewswire/ -- The American Medical Association (AMA) has announced its 2024 Current Procedural Terminology (CPT) code set will include a new Category III code for Avenda Health's innovative Unfold AI™, a cancer AI platform that creates new clinically meaningful insights to aid physicians and patients in making informed treatment decisions. CPT codes are used to report medical procedures and services for processing claims, conducting research, evaluating utilization and developing medical guidelines. The Category III designation is a temporary code for new and developing technologies.

Key Points: 
  • Reimbursement code improves access to personalized prostate cancer care with Avenda Health's AI cancer mapping platform, Unfold AI™
    CULVER CITY, Calif., Nov. 1, 2023 /PRNewswire/ -- The American Medical Association (AMA) has announced its 2024 Current Procedural Terminology (CPT) code set will include a new Category III code for Avenda Health 's innovative Unfold AI™, a cancer AI platform that creates new clinically meaningful insights to aid physicians and patients in making informed treatment decisions.
  • The Category III designation is a temporary code for new and developing technologies.
  • "The new CPT code solidifies our position as a frontrunner in revolutionizing cancer care and our commitment to making our technology accessible to all patients."
  • Avenda plans to expand to major teaching hospitals and urology practices nationwide, ensuring widespread access to advanced cancer care solutions.

Vesica Health Appoints Distinguished Urologic Oncologist Dr. William T. Lowrance to Chief Medical Officer

Retrieved on: 
Dienstag, Oktober 31, 2023
Education minister, Harvard School of Dental Medicine, Survival, Huntsman Cancer Institute, Lee University, Hematuria, MPH, American Urological Association, Public health, Master of Business Administration, Hope, Memorial Sloan Kettering Cancer Center, Medical degree, Prostate cancer, Medical University of South Carolina, Bladder cancer, Bon, MBA, Health, Vesica, Memorial, Disease, Risk, Business administration, Business, University, Public, David Eccles School of Business, Medical school, HEALTH, Lowrance Electronics, Liquid biopsy, Patient, Diagnosis, Associate, Vanderbilt University Medical Center, Harvard T.H. Chan School of Public Health, Pharmaceutical industry, Nursing, Urology, MD, Chemistry

Dr. Lowrance brings more than 20 years of clinical experience, as a professor of urology and a practicing urologic oncologist, treating patients and conducting clinical trials.

Key Points: 
  • Dr. Lowrance brings more than 20 years of clinical experience, as a professor of urology and a practicing urologic oncologist, treating patients and conducting clinical trials.
  • "I have devoted my career to researching and treating urologic cancers, striving to improve patient care and ultimately, survival," said Dr. William T. Lowrance, Chief Medical Officer of Vesica Health.
  • Dr. Lowrance is an attending urologic oncologist at Bon Secours Mercy Health, specializing in the treatment of urologic malignancies, with a focus on bladder cancer.
  • While serving as the Chief Medical Officer of Vesica Health, Dr. Lowrance will continue his medical practice at Bon Secours Mercy Health.

Vesica Health Announces Publication of Study Demonstrating AssureDx Meaningfully Improves Identification of Hematuria Patients at High Risk for Bladder Cancer

Retrieved on: 
Montag, Oktober 9, 2023
OTX1, Probability, AUA, Physician, Department of Urology, University of Virginia, National Capital FreeNet, American Urological Association, TERT, Johns Hopkins University, DNA, Risk, AUC, Capital city, Microhematuria, Urology, Hematuria, Health, HEALTH, Cancer, Carcinoma, TWIST1, Alvin J. Siteman Cancer Center, HRAS, DNA methylation, European Urology, Medical school, Patient, Bladder cancer, FGFR3, Liquid biopsy, Risk assessment, Barnes-Jewish Hospital

The study titled "A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines" was published in the journal European Urology Oncology.

Key Points: 
  • The study titled "A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines" was published in the journal European Urology Oncology.
  • The study analyzed a prospectively collected cohort of 838 hematuria subjects previously tested by AssureDx.
  • Subjects were classified into the AUA risk categories for bladder cancer based on their sex, age, and type of hematuria, also known as urothelial carcinoma (UC).
  • "Publication of this pivotal study in a leading international urology journal, demonstrating AssureDx enhances the AUA Guidelines, underscores the importance of the test for risk stratification of hematuria patients and identification of those at increased risk for bladder cancer," stated Christopher Thibodeau, Chief Executive Officer of Vesica Health.

Novel iTind Procedure Now Included in Treatment Guideline for Lower Urinary Tract Symptoms Caused by Enlarged Prostate

Retrieved on: 
Donnerstag, September 28, 2023
Urine, BPH, AUA, LUTS, Urination, Quality of life, Urinary tract infection, American Urological Association, Olympus Corporation, Research, Prostate, National Prostate Health Month, Patient, Physician, Blood, Ageing, Medical imaging

CENTER VALLEY, Pa., Sept. 28, 2023 /PRNewswire/ -- Olympus Corporation, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced today that its iTind™ procedure is now included in the American Urological Association (AUA) clinical practice guideline for management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), also known as enlarged prostate. The iTind procedure is reflected in the new procedure category, Temporary Implanted Prostatic Devices (TIPD).i The addition of the TIPD category is based on expert opinion reflecting peer-reviewed treatment recommendations and research updates.

Key Points: 
  • The iTind procedure is reflected in the new procedure category, Temporary Implanted Prostatic Devices (TIPD).i The addition of the TIPD category is based on expert opinion reflecting peer-reviewed treatment recommendations and research updates.
  • The minimally invasive iTind procedure involves the placement of a temporarily implanted nitinol device that reshapes the prostatic urethra without burning or cutting out the prostate.
  • "This guidance reflects compelling clinical evidence and positive clinical experience with the iTind procedure."
  • In rare cases, the iTind device may cause urinary tract infection or a sudden difficulty to urinate.

Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ

Retrieved on: 
Mittwoch, September 20, 2023
American Urological Association, Cancer, CIS, BCG, Patient, Annual general meeting, CR, Rare, Therapy, Safety, Pharmaceutical industry, Vaccine, NMIBC

In addition, dosing is progressing in the ongoing ADVANCED-EXP trial started earlier this year with preliminary results expected in the first half of 2024.

Key Points: 
  • In addition, dosing is progressing in the ongoing ADVANCED-EXP trial started earlier this year with preliminary results expected in the first half of 2024.
  • “There is significant need for new intravesical approaches for NMIBC, which can recur and progress to invasive disease with current treatments.
  • “Following positive preliminary results from the ADVANCED-1 trial, we are pleased to have dosed the first patient in the ADVANCED-2 trial,” said Jathin Bandari, M.D., Chief Medical Officer of Protara Therapeutics.
  • The ongoing ADVANCED-1EXP trial is a Phase 1b open-label expansion trial evaluating intravesical TARA-002 in 12 CIS patients, including BCG-naïve, BCG-unresponsive, and BCG-inadequately treated patients.

United Urology Group and Its Affiliate Practices and Prostate Centers USA® are collaborating to Revolutionizing Men's Health Care with Minimally Invasive Solutions

Retrieved on: 
Freitag, September 15, 2023
PAE, Prostatic artery embolization, Patient satisfaction, BPH, Quality of life, American Urological Association, Prostate, Quality, Patient, Physician, Urology, UUG, Health, Dairy, Nursing

"We are thrilled to engage with Prostate Centers USA® as a leader in minimally invasive men's health care.

Key Points: 
  • "We are thrilled to engage with Prostate Centers USA® as a leader in minimally invasive men's health care.
  • By collaborating with Prostate Centers USA®, our Affiliate Practices are able to offer advanced and effective treatment options for men suffering from an enlarged prostate.
  • UUG Affiliate Practices and Prostate Centers USA® are at the forefront of delivering exceptional results in men's health care.
  • UUG's Affiliated Practices and Prostate Centers USA® are dedicated to advancing the field of men's health care through continuous innovation and collaboration.

AUA Releases Amendment to the Diagnosis and Treatment of Early-Stage Testicular Cancer Guideline

Retrieved on: 
Donnerstag, September 14, 2023
Cancer, IIB, Teratoma, Guideline, Retroperitoneal space, AUA, IIA, American Urological Association, Bleomycin, Toxicity, Cisplatin, Literature, SUFU, Testicular cancer, Etoposide, Estate (law), Patient, Surveillance, Diagnosis, Rush University Medical Center, Tumor antigen, ULR, Dentistry, Medical imaging, Medical device

BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and treatment of early-stage testicular cancer.

Key Points: 
  • BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the diagnosis and treatment of early-stage testicular cancer.
  • Testicular cancer is the most common solid malignancy in young males and is relatively rare, with outcomes defined by specific cancer and patient-related factors.
  • "Since the last testicular cancer guideline was released, the model for management has substantially changed, making an amendment like this critical to effectively treat and manage testicular cancer."
  • Diagnosis and treatment of early-stage testicular cancer: AUA Guideline amendment 2023.

AUA Releases Amendment to the Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia Guideline

Retrieved on: 
Donnerstag, September 14, 2023
PAE, Male, Prostatic artery embolization, Prevalence, Guideline, E pluribus unum, Epithelium, AUA, BPH, LUTS, Urethra, Ageing, American Urological Association, Prostate, Literature, MD, Patient, Finasteride, Water, Memorial Sloan Kettering Cancer Center, Diagnosis, Benign prostatic hyperplasia, System, ULR, Update, Medical imaging, Dietary supplement

BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia.

Key Points: 
  • BALTIMORE, Sept. 14, 2023 /PRNewswire/ -- Today the American Urological Association (AUA) released the 2023 clinical practice guideline amendment for the management of lower urinary tract symptoms attributed to benign prostatic hyperplasia.
  • Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the production of smooth muscle and epithelial cells within the prostatic transition zone.
  • The prevalence and the severity of lower urinary tract symptoms (LUTS) in the aging male can be progressive and is an important diagnosis in the healthcare of patients and the welfare of society.
  • Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA Guideline amendment 2023.

September is Prostate Cancer Awareness Month

Retrieved on: 
Freitag, September 1, 2023
Prostate cancer, AUA, Skin cancer, Cancer, Lung cancer, American Urological Association, Risk, Prostate, Death, Incidence, Active surveillance of prostate cancer, Disease, Dairy, MD

"Prostate cancer is the most commonly diagnosed cancer in men next to skin cancer," said Harris M. Nagler, MD, President of the Urology Care Foundation.

Key Points: 
  • "Prostate cancer is the most commonly diagnosed cancer in men next to skin cancer," said Harris M. Nagler, MD, President of the Urology Care Foundation.
  • Since 2014, the incidence rate of prostate cancer has increased by 3% per year overall and by about 5% per year for advanced-stage prostate cancer.
  • Talk to your doctor about prostate cancer screening if you are age 40 to 54 years and:
    Black men are 17x more likely to be diagnosed with prostate cancer and are 2.1x more likely to die from prostate cancer than white men.
  • For everything you need to know about prostate cancer, check out the Urology Care Foundation's Prostate Cancer Info Center , and scroll through its Twitter, Facebook and Instagram platforms for free prostate cancer resources, including fact sheets, podcasts, videos and more.